By using anti-MIF antibodies to neutralize MIF, it has been demonstrated that TNF-α production and the build-up of neutrophils can be reduced, resulting in the alleviation of symptoms and improved prognosis for sepsis-related ARDS patients, ultimately reducing the likelihood of mortality. The gene discussed is TNF; the disease is acute respiratory distress syndrome.